part_subject: "ANTIEMETIC DRUG PRODUCTS FOR OVER-THE-COUNTER HUMAN USE"
subpart_code: "C"
subpart_subject: "Labeling"
section_number: "336.80"
section_subject: "Professional labeling."
cfr_reference: "21 CFR 336.80"
title_name: "Title 21"
title_subject: "Food and Drugs"
parts_covered: "Parts 300 to 499"
revised_date: "Revised as of April 1, 2019"
publication_date: "As of April 1, 2019"
contains_description: "Containing a codification of documents of general applicability and future effect"
publication_info: "Published by the Office of the Federal Register National Archives and Records Administration as a Special Edition of the Federal Register"
---
The labeling provided to health professionals (but not to the general public) may contain the following additional indications.
(a)For products containing cyclizine hydrochloride, dimenhydrinate, and diphenhydramine hydrochloride identified in § 336.10 (a), (b), and (c). “For the treatment of vertigo of motion sickness.”
(b)For products containing meclizine hydrochloride identified in § 336.10(d). “For the treatment of vertigo.”